

1 **A germline heterozygous dominant negative *IKZF2* variant causing**
2 **syndromic primary immune regulatory disorder and ICHAD**

3 Henry Y. Lu^{1,2}, Maryam Vaseghi-Shanjani^{1,2}, Avery J. Lam^{3,4}, Meहुल Sharma^{1,2}, Arezoo
4 Mohajeri⁵, Jana Gillies^{3,4}, Gui Xiang Yang⁵, Susan Lin¹, Maggie P. Fu^{5,6,7}, Areesha
5 Salman⁵, Ronak Rahmanian⁸, Linlea Armstrong⁵, Jessica Halparin^{1,9}, Connie L. Yang^{1,9},
6 Mark Chilvers^{1,10}, Erika Henkelman¹¹, Wingfield Rehmus^{1,12}, Douglas Morrison^{1,13}, Audi
7 Setiadi^{1,13}, Sara Mostafavi^{5,14}, Michael S. Kobor^{5,7}, Frederick K. Kozak⁸, Catherine M.
8 Biggs^{1,15}, Clara van Karnebeek^{1,7}, Kyla J. Hildebrand^{1,15}, Anna Lehman on behalf of the
9 Care4Rare Canada Consortium⁵, Megan K. Levings^{3,4,16}, Stuart E. Turvey^{1,2,14}

10 ¹Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
11 Vancouver, BC, Canada

12 ²Experimental Medicine Program, Faculty of Medicine, The University of British
13 Columbia, Vancouver, BC, Canada

14 ³BC Children's Hospital Research Institute, Vancouver, BC, Canada

15 ⁴Department of Surgery, The University of British Columbia, Vancouver, BC, Canada

16 ⁵Department of Medical Genetics, The University of British Columbia, Vancouver, BC,
17 Canada

18 ⁶Genome Science and Technology Program, Faculty of Science, The University of
19 British Columbia, Vancouver, BC, Canada

20 ⁷Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada

21 ⁸Division of Otolaryngology – Head & Neck Surgery, BC Children's Hospital, The
22 University of British Columbia, Vancouver, BC, Canada

23 ⁹Division of Hematology, Oncology & Bone Marrow Transplant, BC Children's Hospital,
24 The University of British Columbia, Vancouver, BC, Canada

25 ¹⁰Division of Respiratory Medicine, BC Children's Hospital, The University of British
26 Columbia, Vancouver, BC, Canada

27 ¹¹Division of Plastic Surgery, BC Children's Hospital, The University of British Columbia,
28 Vancouver, BC, Canada

29 ¹²Division of Dermatology, BC Children's Hospital, The University of British Columbia,
30 Vancouver, BC, Canada

31 ¹³Department of Pathology and Laboratory Medicine, BC Children's Hospital, The
32 University of British Columbia, Vancouver, BC, Canada

33 ¹⁴Department of Statistics, The University of British Columbia, Vancouver, BC, Canada

34 ¹⁵Division of Allergy and Clinical Immunology, BC Children's Hospital, The University of
35 British Columbia, Vancouver, BC, Canada

36 ¹⁶School of Biomedical Engineering, The University of British Columbia, Vancouver, BC,
37 Canada

38

39

40

41 **Correspondence to:** Stuart E. Turvey, MBBS, DPhil, FRCPC
42 BC Children's Hospital
43 950 West 28th Avenue
44 Vancouver, BC, V5Z 4H4, Canada
45 Phone: 604 875 2345 ext. 5094
46 Email: sturvey@bcchr.ca

47 **Word count:** 4107

48 **Reference count:** 52

49 **Abstract:**

50 Monogenic defects that impair the control of inflammation and tolerance lead to
51 profound immune dysregulation, including autoimmunity and atopy. Studying these
52 disorders reveals important molecular and cellular factors that regulate human immune
53 homeostasis and identifies potential precision medicine targets. Here, we provide a
54 detailed immunological assessment of a pediatric patient with a recently discovered
55 syndrome causing Immunodysregulation, Craniofacial anomalies, Hearing impairment,
56 Athelia, and Developmental delay (or ICHAD syndrome). The immunodysregulation
57 resulted in autoimmune hemolytic anemia (AIHA) and atopic dermatitis. The patient
58 carried a *de novo* germline heterozygous
59 c.406+540_574+13477dup;p.Gly136_Ser191dup variant in *IKAROS family zinc finger 2*
60 (*IKZF2*), which encodes Helios. This variant led to reduced Helios protein expression
61 and dominant interference of wild-type Helios-mediated repression of the *IL2* promoter.
62 Multi-parameter flow cytometric analyses of patient peripheral blood mononuclear cells
63 revealed strongly impaired natural killer cell differentiation and function, and increased
64 CD8⁺ T cell activation and cytokine secretion. Strikingly, patient CD4⁺ T cells were
65 hyperactive, produced elevated levels of nearly all T helper (T_H) cytokines, and readily
66 proliferated in response to stimulation. Patient regulatory T cells (Tregs) developed
67 normally but aberrantly produced high levels of many T_H cytokines. Single-cell RNA
68 sequencing revealed largely normal Tregs (albeit mostly memory), but naïve CD4⁺ T
69 cells that were more enriched in genes related to activation, proliferation, metabolism,
70 and T_H differentiation. This work describes the immunological phenotype of one of the
71 first reported cases of germline dominant negative Helios deficiency, expands our
72 understanding of the pathogenesis of AIHA on a single cell level, and provides valuable
73 insights into Helios function in a variety of lymphocyte subsets.

74

75 INTRODUCTION

76 Immunity is tightly regulated to optimize protective responses against pathogens and
77 malignancy while preventing inappropriate responses to otherwise benign antigens.
78 Monogenic defects that impair this regulation of inflammation or tolerance result in a
79 subgroup of the inborn errors of immunity (IEI) called primary immune regulatory
80 disorders (PIRD)¹. In contrast to classic IEIs, which typically manifest as unusually
81 severe or recurrent infections, PIRDs predominantly present with immune-mediated
82 pathology, including autoimmunity, lymphoproliferation, malignancy, autoinflammation,
83 and atopy, with susceptibility to infections being a less pronounced aspect of these
84 disorders².

85 Immune dysregulation can lead to a variety of hematologic manifestations and
86 cytopenias³. A classic example is autoimmune hemolytic anemia (AIHA) caused by
87 immune-mediated destruction of erythrocytes⁴. AIHA can be idiopathic (primary) or
88 secondary and is classified as warm or cold (cold agglutinin disease [CAD], paroxysmal
89 cold hemoglobinuria) depending on autoantibody behaviour at different thermal ranges,
90 which is important for determining appropriate treatment regimens⁵. Most cases of AIHA
91 are considered idiopathic (~60%)⁶, while secondary causes can include IEIs/PIRDs,
92 malignancy, bacterial/viral infections, and drugs⁴. As such, the etiology and
93 pathogenesis of AIHA remains incompletely understood.

94 In the past 2 years, human germline variants in a family of transcription factors called
95 the IKAROS zinc finger (IKZF) family have been linked to immunodeficiency and
96 cytopenias⁷⁻¹⁰. Notably, loss-of-function (LOF) variants in *IKZF2* (Helios) were recently
97 associated with combined immunodeficiency (CID) and/or immune dysregulation,
98 including immune thrombocytopenia (ITP), Evan's syndrome, and systemic lupus
99 erythematosus⁷⁻⁹. *IKZF2* is highly expressed in hematopoietic stem/progenitor cells, T
100 cells, including activated CD4⁺/CD8⁺ T cells, mucosa-associated invariant T (MAIT)
101 cells, regulatory T cells (Tregs), and natural killer (NK) cells¹¹⁻¹⁶. As Tregs are among
102 the highest *IKZF2* expressors, most studies have focused on the role of Helios in Treg
103 development and function¹⁷⁻²⁷. In mice, Helios is critical for Treg identity, survival, and
104 stability, but is seemingly dispensable in mice and humans for suppressive function^{20,27}.

105 Nevertheless, both *IKZF2*^{-/-} and Treg-specific *IKZF2*^{-/-} mice develop progressive
106 autoimmune disease associated with activated CD4⁺/CD8⁺ T cells, increased T follicular
107 helper (T_{FH}) and germinal center (GC) B cell numbers, autoantibody production, and
108 increased proinflammatory cytokine production^{19,20,28}. The role of *IKZF2* in other
109 components of the human immune system (e.g. NK cells) is beginning to be better
110 defined through the identification of humans with germline *IKZF2* variants⁷⁻¹⁰.

111 Here, we report a detailed immunological and mechanistic workup of the first reported
112 case of germline heterozygous dominant negative (DN) *IKZF2* disorder in a young girl
113 we recently described¹⁰. This patient was found to have a novel genetic syndrome
114 comprising Immunodysregulation, Craniofacial anomalies, Hearing impairment, Athelia,
115 and Developmental delay (or ICHAD syndrome). We report a comprehensive
116 mechanistic immune evaluation of this patient which revealed significant developmental
117 and functional defects in NK and naïve CD4⁺ T cells and marked immune activation as
118 the likely cause of immune dysregulation. Informed by our improved appreciation of the
119 human phenotype caused by germline *IKZF2* variants, we suggest that germline
120 heterozygous dominant negative *IKZF2* variants should now be considered in the
121 differential diagnosis of patients with AIHA and PIRD.

122

123 **METHODS**

124 **Study participants and consent**

125 All study participants and/or their parents/guardians provided written informed consent.
126 Research study protocols (H18-02853, H18-02912, H15-00092) were approved by The
127 University of British Columbia Clinical Research Ethics Board.

128 **Cell isolation, culture, and immortalization**

129 Peripheral blood mononuclear cells (PBMCs) were isolated from all study participants
130 by standard Ficoll-Paque (GE Healthcare) density centrifugation as previously
131 described²⁹. Lymphoblastoid cell lines (LCLs) were derived by standard EBV
132 transformation as previously described²⁹ (**Supplement**).

133 **Plasmid generation and cloning**

134 WT *IKZF2*, p.Gly136_Ser191dup *IKZF2*, pIL2-Luc2 plasmids were generated by
135 introducing restriction sites into cDNA or genomic DNA by PCR and cloning into
136 pCMV6-XL4-3xFLAG and p.GL4.14 firefly luciferase gene reporter (Promega) vectors,
137 respectively (**Supplement**).

138 **Transient transfections**

139 HEK293 cells were transfected with empty vector (EV), WT, p.Gly136_Ser191dup, or
140 varying ratios of WT/p.Gly136_Ser191dup *IKZF2* expression plasmids by Lipofectamine
141 3000 (ThermoFisher) transfection (**Supplement**). Transfected cells were then
142 processed for immunoblotting or immunofluorescence. For luciferase assays, cells were
143 additionally transfected with pIL2-Luc2 and Renilla luciferase (R-Luc) plasmids then
144 processed with a Dual-Glo Luciferase Assay Kit (#E2920, Promega) (**Supplement**).

145 **Immunoblotting**

146 Helios protein detection was accomplished in LCLs and transfected HEK293 cells by
147 standard immunoblotting as previously described²⁹ (**Supplement**).

148 **Immunofluorescence**

149 12mm coverslips were sterilized, HEK293 cells were seeded on top in 6-well plates,
150 allowed to attach for 24h, then transfected as above. Transfected cells were fixed,

151 permeabilized, and stained for Helios, DAPI, and F-actin before mounting and imaging
152 on a Leica SP5 II Laser Scanning Confocal Microscope (Leica Microsystems GmbH)
153 (**Supplement**).

154 **Immunophenotyping**

155 Immunophenotyping and intracellular cytokine was performed as previously described³⁰.
156 Briefly, PBMCs were stimulated with PMA and ionomycin (P/I) in the presence of
157 GolgiStop (#554724, BD Biosciences), stained with antibody panels 1-4 (**Supplemental**
158 **Table 5**) using the eBioscience Foxp3 Transcription Factor Staining Buffer Set (#00-
159 5523-00, Invitrogen, ThermoFisher), acquired on a FACSymphony flow cytometer, and
160 analyzed using FlowJo (both BD Biosciences) (**Supplement**).

161 **Proliferation assays**

162 PBMCs were seeded at varying concentrations, labelled with Cell Proliferation Dye
163 (CPD) eF450 (#65-0842-85, Invitrogen, ThermoFisher) and stimulated with anti-
164 CD3/CD28-coated Dynabeads (#11141D, Human T-Expander, Gibco, ThermoFisher)
165 for four days. Cells were stained with antibody panel 6 (**Supplemental Table 5**) and
166 acquired on a CytoFLEX (Beckman Coulter) and analyzed using FlowJo (**Supplement**).

167 **T cell suppression assays**

168 Treg suppression of CD3⁺ T cell proliferation was assessed as previously described²⁷.
169 Briefly, patient and control PBMCs were enriched for CD4⁺ T cells, sorted using panel 7
170 (**Supplemental Table 5**) for Tregs and Tconvs, expanded with IL-2 and irradiated
171 mouse L cells for seven days, then cocultured with various ratios of CPD-labelled anti-
172 CD3/CD28 Dynabead-stimulated enriched CD3⁺ T responder (Tresp) cells for four days.
173 Percent suppression of CD4⁺ and CD8⁺ T cell proliferation was calculated using division
174 index (DI): $(1 - [\text{DI of sample}/\text{DI of positive control}]) \times 100\%$ (**Supplement**).

175 **Quantification of cytokine production**

176 Supernatants were collected from PBMCs stimulated for proliferation, cocultured Tregs
177 and Tresp for T cell suppression assays, and stimulated Tregs and Tconvs alone.
178 Cytokine concentrations were measured by LEGENDplex Human Th Cytokine Panel
179 12-plex (#741027, BioLegend) on a CytoFLEX (Beckman Coulter) and analyzed with

180 Qognit software (BioLegend) according to manufacturer's recommendations
181 **(Supplement)**.

182 **TSDR methylation**

183 Genomic DNA was isolated from expanded Tregs and Tconvs, bisulfite converted with
184 an EZ DNA Methylation-Direct Kit (Zymo Research), PCR amplified, and
185 pyrosequenced using a PyroMark Q96 MD (Qiagen) as previously described²⁷
186 **(Supplement)**.

187 **Single-cell RNA sequencing**

188 Single-cell RNA sequencing was performed on unstimulated and 4h P/I-stimulated
189 sorted Tregs and Tconv from P1 and two age-matched/sex-matched controls using the
190 BD Rhapsody Single Cell platform (BD Biosciences) according to manufacturer's
191 recommendations and analyzed as previously described³⁰ **(Supplement)**. Raw data are
192 deposited on Gene Expression Omnibus.

193

194 RESULTS

195 Clinical case presentation

196 The index patient (P1) is a 5-10-year-old girl born to non-consanguineous parents
197 (**Figure 1A**) who presented with syndromic features of developmental abnormalities and
198 immune dysregulation. Family history is unremarkable. She has profound bilateral
199 sensorineural hearing loss, microcephaly, mild developmental delay, cleft palate,
200 hypotonia, athelia, and dysmorphic facies (detailed in¹⁰). Consistent with underlying
201 immune dysregulation, she has suffered from chronic anemia beginning at two months
202 of age, which at times required hospitalization and red blood cell transfusions (**Figure**
203 **1B-I**). She also had severe atopic dermatitis beginning at ten months of age affecting
204 the face, arms, legs, and trunk. Her skin inflammation was initially refractory to optimal
205 medical therapy (i.e. topical corticosteroids, emollients, bleach baths), but has become
206 more manageable with age. The patient also experienced frequent upper respiratory
207 tract infections, which reduced in frequency following initiation of monthly intravenous
208 immunoglobulin (IVIG) replacement therapy. Laboratory and hematologic evaluation
209 revealed chronically positive direct antiglobulin tests (DAT) initially consistent with a
210 mixed (cold>warm) AIHA phenotype, which progressed to a predominantly warm AIHA
211 phenotype with age without overt hemolysis. Other notable hematological features
212 included a normocellular bone marrow with scattered hemophagocytic macrophages, no
213 morphological evidence for dysplastic cells or a progressive marrow disorder,
214 lymphopenia, and elevated IgE (**Table 1**). Red cells did not carry any hemoglobin
215 variants, although non-specific poikilocytosis and rouleaux formation were noted.

216 Given the unique constellation of features, P1 underwent trio WGS (detailed in¹⁰). This
217 revealed a novel *de novo* germline heterozygous structural variant affecting *IKAROS*
218 *zinc finger 2 (IKZF2)* encoding Helios (NM_016260.3:c.406+540_574+13477dup;
219 NP_057344.2:p.Gly136_Ser191dup) (**Figure 1J-K**). The variant results in intron 5 at
220 chr2:213900960 being joined to intron 6 chr2:213921017 (GRCh37) with a 2 bp GT
221 insertion in between. This leads to tandem duplication of exon 5 (~20kb duplication
222 spanning exon 5 and parts of flanking introns), corresponding to tandem duplication of
223 zinc fingers 2 and 3 of Helios (**Figure 1K**).

224 **Characterization of the impact of the p.Gly136_Ser191dup Helios variant on** 225 **protein expression and localization**

226 The p.Gly136_Ser191dup Helios variant created a higher molecular weight Helios
227 protein (as anticipated with a ~13kDa 56 amino acid duplication) detected in both
228 transfected HEK293 cells and primary patient-derived LCLs (**Figure 2A, C** and detailed
229 in¹⁰). Total Helios protein expression was reduced overall in both transfected HEK293
230 (**Figure 2A-B**) and patient-derived LCLs (**Figure 2C-E**), likely because the variant
231 protein was less stable. As a TF, Helios localizes to the nucleus to regulate
232 transcription¹². We transfected HEK293 cells with WT or p.Gly136_Ser191dup *IKZF2*
233 alone, or increasing quantities of p.Gly136_Ser191dup together with WT *IKZF2* (**Figure**
234 **2F**) to assess protein expression by immunofluorescence. The variant protein was
235 indistinguishable from WT protein in nuclear localization, nor did it affect the nuclear
236 localization of WT protein.

237 **p.Gly136_Val192dup Helios acts through dominant interference**

238 Helios has previously been shown to bind the *IL2* promoter to silence IL-2 production in
239 Tregs³². We therefore cloned the human *IL2* promoter (-580 bp to +57 bp) into a firefly
240 luciferase gene reporter vector and cotransfected this with Renilla luciferase, WT or
241 p.Gly136_Ser191dup *IKZF2* alone, or p.Gly136_Ser191dup together with WT (**Figure**
242 **2G** and detailed in¹⁰). As expected, WT *IKZF2* strongly repressed *IL2* promoter activity.
243 However, p.Gly136_Val192dup not only showed impaired repression on its own, but
244 significantly interfered with WT *IKZF2*-mediated *IL2* repression (**Figure 2G**). This DN
245 effect was dose-dependent, with increasing quantities of p.Gly136_Ser191dup
246 transfected correlating with more impaired WT *IKZF2*-dependent *IL2* repression
247 ($r^2=0.94$, $p<0.0005$) (**Figure 2H** and detailed in¹⁰).

248 **Patient lymphocyte phenotyping reveals NK cell lymphocytosis and CD3⁺ T cell** 249 **lymphopenia**

250 Helios is highly expressed in CD3⁺ T cells and NK cells¹¹, both of which are known to be
251 dysregulated in AIHA⁴. We profiled the frequencies of CD3⁺ T, CD3⁻CD56⁺ NK, and
252 CD3⁺CD56⁺ NKT cells as well as Helios expression from P1 (n=5 independent blood
253 draws) and a cohort of adult (n=8) and age-matched controls (n=11). P1 had

254 significantly reduced frequencies of CD3⁺ T (**Figure 3A-B**), markedly elevated NK
255 (**Figure 3A,C**), and modestly elevated NKT (**Figure 3A,D**) cells, all of which were
256 Helios-deficient (**Figure 3E-H**).

257 **P1 NK cells are phenotypically immature and functionally abnormal**

258 Given the intriguing NK cell lymphocytosis, we set out to define the developmental and
259 functional status of P1 NK cells by assessing the expression of CD56, maturation
260 (CD27, CD57, CD94), adhesion (CD16), and activation (CD8, CD25) markers³³⁻³⁵ on P1
261 NK cells compared to controls. The relative abundance of CD56^{dim} and CD56^{bright} NK
262 cell populations was normal (**Figure 3I-J**), although on histograms, the patient lacked a
263 clear CD56^{bright} population (**Figure S1A**). Strikingly, all maturation markers assessed
264 were dysregulated in P1, including significantly reduced CD16⁺ (**Figure 3K, Figure**
265 **S1B**) and CD57⁺ (**Figure 3L, Figure S1C**), but elevated CD27⁺ (**Figure 3M, Figure**
266 **S1D**) and CD94⁺ (**Figure 3N, Figure S1E**) NK cells. Similarly, the frequency of CD8⁺
267 NK cells were significantly reduced in the patient both at baseline and in response to
268 stimulation (**Figure 3O, Figure S1F**), while CD25⁺ NK cells (**Figure 3P, Figure S1G**)
269 were normal. This abnormal distribution of markers disproportionately affected CD56^{dim}
270 NK cells more than CD56^{bright} NK cells, although Helios was reduced in both populations
271 (**Figure S1H-N**). Taken together, patient NK cells are skewed towards an immature
272 phenotype.

273 As NK cells mediate their effector functions through the release of proinflammatory
274 cytokines and cytotoxicity³³, we studied whether these roles were affected in P1. In
275 response to stimulation, P1 had significantly elevated IFN- γ ⁺ NK cells (**Figure 3Q,**
276 **Figure S1O**), but comparable TNF- α ⁺ NK cells (**Figure 3R, Figure S1P**). Similarly, P1
277 NK cells expressed significantly less granzyme B (**Figure 3S**) and perforin (**Figure 3T**),
278 with this effect being more pronounced in CD56^{dim} NK cells (**Figure S1Q-R**). These
279 defects were confirmed in multidimensional space when we clustered live CD3⁺CD56⁺
280 NK cells from P1 and adult and pediatric controls on CD16, CD27, CD57, CD94, Helios,
281 perforin, granzyme B, IFN- γ , and TNF- α at baseline and in response to stimulation
282 (**Figure 3U-V, Figure S1S**).

283 **Patient CD8⁺ T cells are significantly reduced, have high PD-1 expression, and are**
284 **potent proinflammatory cytokine producers**

285 As CD8⁺ T cells are frequently enriched in autoimmune disease³⁶ and can be clonally
286 expanded in AIHA³⁷, we assessed the frequency of CD8⁺ T cells and subsets and their
287 Helios expression. P1 had profound CD8⁺ T cell lymphopenia (**Figure 4A-B**),
288 significantly elevated frequencies of central memory (CM) with a concurrent reduction in
289 naïve subsets, while effector memory (EM) and TEMRA subsets were normal (**Figure**
290 **4C-G**). Importantly, all P1 CD8⁺ T cell subsets were Helios-deficient (**Figure 4H-I**).

291 PD-1 is a critical inhibitory receptor that is upregulated in activated, memory, or
292 exhausted T cells to restrain effector functions³⁸. We therefore assessed PD-1
293 expression and proinflammatory cytokine production in P1 CD8⁺ T cells. In line with
294 elevated CD8 CM, we discovered significantly more PD-1 expression on P1 CD8⁺ T
295 cells (**Figure 4J-K**). These T cells are likely not exhausted as both naïve and total
296 memory CD8⁺ T cells produced significantly more TNF- α (**Figure 4L-N**) and IFN- γ
297 (**Figure 4O-Q**) than controls, while CD8⁺ T cell proliferation was comparable to controls
298 (**Figure 4R-S**).

299 **P1 CD19⁺ B cells show largely normal development but increased TNF- α**
300 **production**

301 Although Ikaros and Aiolos are both critical for B cell differentiation³⁹, the role of Helios
302 in these cells is less clear. Helios silencing is thought to maintain B cell function as
303 ectopic expression leads to B cell hyperresponsiveness and lymphomagenesis⁴⁰. We
304 therefore studied the development and function of P1 B cells. In general, B cell
305 development was largely normal, with intact total CD19⁺ (**Figure S2A-B**), naïve (**Figure**
306 **S2C, D**), switched memory [SM] (**Figure S2C, F**), and plasmablasts (**Figure S2I-J**).
307 However, we did observe significantly increased non-switched memory [NSM] (**Figure**
308 **S2C, E**) and decreased transitional B cells (**Figure S2G-H**), while Helios was lowly
309 expressed in all B cell populations from both P1 and controls (**Figure S2K-L**). In
310 response to stimulation, patient B cells produced significantly more TNF- α than controls
311 (**Figure S2M**). This applied to NSM (**Figure S2N**), SM (**Figure S2O**), and naïve (**Figure**
312 **S2P**) subsets.

313 **P1 CD4⁺ T cells are more mature**

314 CD4⁺ T helper (T_H) cells and their subsets are critical for both protective antimicrobial
315 immunity and driving pathological states such as autoimmunity and atopic disease⁴¹.
316 We therefore enumerated the frequency of total CD4⁺ T cells and subsets and Helios
317 expression. P1 CD4⁺ T cells were modestly elevated (**Figure 5A**) in line with CD8⁺ T
318 lymphopenia. We also found similar subset distributions to P1 CD8⁺ T cells, including
319 significantly increased CD4⁺ CM (**Figure 5B, D**), with an associated reduction in naïve
320 (**Figure 5B, C**), while EM and TEMRA subsets (**Figure 5E-F**) were normal. Helios
321 expression was low in all CD4⁺ subsets (**Figure 5G-H**).

322 **P1 CD4⁺ T cells are hyperresponsive and exhibit effector phenotypes**

323 In mice, Treg-specific, but not complete knockout, of *Ikzf2* in mice leads to increased
324 PD-1 expression on CD4⁺ T cells²⁰. Surprisingly, P1 had three-fold higher PD-1⁺ CD4⁺ T
325 cells than controls (**Figure 5I-J**), which could signify higher activation status. We thus
326 measured the frequency of T_H subsets and cytokine production. Mirroring our *IL2*
327 promoter luciferase data (**Figure 2F-G**), we observed a striking increase in IL-2⁺ CD4⁺ T
328 cells in P1 (**Figure 5K-L**). This was not limited to IL-2, as the patient also had
329 significantly increased IFN- γ ⁺ and TNF- α ⁺ CD4⁺ T cells (**Figure 5M-P**) and most T_H
330 subsets, including T_{H1}, T_{H2} (**Figure 5Q-S**), T_{H9}, T_{FH} (**Figure 5T-V**), and T_{H17} (**Figure**
331 **S3A-B**). This also held true when we measured T_H cytokines in the supernatant of
332 stimulated PBMCs, where we found markedly elevated concentrations of IL-2, IL-4, IL-5,
333 IL-6, IL-9, IL-13, and TNF- α , even in response to lower bead:cell ratios (**Figure 5W,**
334 **Figure S3C-N**). Surprisingly, we observed marked impairment in secreted IL-22 levels
335 (**Figure S3L**). In keeping with this picture of hyperactive CD4⁺ T cells, P1 CD4⁺ T cells
336 more readily proliferated in response to stimulation than controls (97.1% divided in
337 patient vs. 54.5% in control) (**Figure 5X-Y**).

338 **P1 has normal Treg frequencies and TSDR methylation**

339 ~70-80% of Tregs express Helios and at least in mice, this is thought to be important for
340 regulating Treg identity and function⁴². As Tregs are critical mediators of
341 tolerance/homeostasis and their dysfunction is associated with allergic and autoimmune
342 disease⁴³, we enumerated their frequency and Helios expression in P1. P1 had normal

343 frequencies of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺ Tregs (**Figure 6A, Figure S4A**),
344 but significantly reduced Helios expression (**Figure 6B-C**).

345 Since methylation of the Treg-specific demethylated region (TSDR) in the *FOXP3* gene
346 is important for maintaining stable FOXP3 expression and Treg suppressive
347 function^{44,45}, we quantified expanded P1 Treg TSDR methylation and FOXP3
348 expression in comparison to Tregs from healthy female controls. TSDR methylation was
349 normal (**Figure 6D**), although the average methylation trended to higher in P1 (**Figure**
350 **S4B**). *Ex vivo* P1 Tregs had significantly higher FOXP3 expression than controls, likely
351 reflecting a higher state of activation (**Figure 6E**).

352 **P1 Tregs are predominantly PD-1⁺ and are potent T_H cytokine producers**

353 Given the striking increase in PD-1⁺ CD4⁺ (**Figure 5I-J**) and CD8⁺ (**Figure 4J-K**) T cells
354 in P1, we assessed PD-1 expression in P1 *ex vivo* Tregs. Similarly, P1 had significantly
355 more PD-1⁺ Tregs (~80%) than controls (~40%) (**Figure 6F, Figure S4C**). Helios
356 genetic or pharmacological targeting in Tregs leads to elevated IL-2³², IFN- γ , and IL-
357 17A^{19,20,28,46} and effector T_H cell signatures⁴⁷. We thus studied T_H cytokine production in
358 *ex vivo* Tregs and discovered significantly elevated IL-2⁺ Tregs in P1 (**Figure 6G-H**),
359 confirming our *IL2* luciferase data (**Figure 2F-G**). P1 also had a striking increase in IL-4⁺
360 (**Figure 6I-J**), IFN- γ ⁺ (**Figure 6I, K**), IL-9⁺ (**Figure 6L, Figure S4D**), IL-21⁺ (**Figure 6M,**
361 **Figure S4D**), and TNF- α ⁺ (**Figure 6N-O**) Tregs. Expanded P1 Tregs also produced
362 higher concentrations of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, and IL-17F (**Figure 6P,**
363 **Figure S4C-N**).

364 **P1 Tregs have impaired suppressive function are not intrinsically resistant to** 365 **being suppressed**

366 The abnormal cytokine production in P1 Tregs prompted us to investigate their ability to
367 suppress T responder (Tresp) proliferation and cytokine production. We cocultured
368 expanded P1 and control Tregs at different ratios with stimulated control CD3⁺ Tresp.
369 We discovered no significant differences between patient or control Treg-mediated
370 suppression of CD4⁺ (**Figure 6Q**) or CD8⁺ (**Figure 6R**) T cell proliferation, although
371 suppression trended to lower in the 1:2.5 and 1:5 Treg:CD3 T cell ratios.

372 An intrinsic resistance to Treg-mediated suppression could also contribute to the
373 patient's prominent hyperactivation phenotype. We reversed our setup from above and
374 cocultured control Tregs with P1 CD3⁺ Tresp and measured suppression of T_H
375 cytokines. P1 T_H cytokine production was effectively suppressed by control Tregs
376 (**Figure 6S, Figure S5**), excluding an intrinsic defect in susceptibility to suppression.

377 **scRNA-seq reveals a predominantly memory and effector phenotype in P1 Tregs**

378 To assess transcriptomic pathways that could drive the striking patient Treg phenotype,
379 we sorted CD4⁺CD25⁺CD127^{lo} Tregs from P1 and two age-matched/sex-matched
380 controls (**Figure S6A**). We carried out whole transcriptome single-cell RNA sequencing
381 (scRNA-seq) on Tregs from P1 (n=295 cells) and controls (n=331 cells) and performed
382 dimensionality reduction using the uniform manifold approximation and projection
383 (UMAP) method⁴⁸. Patient Tregs clustered separately from controls (**Figure 7A**) and
384 when cell identity was annotated using the DICE project⁴⁹, they were predominantly
385 labelled as memory Treg and T_H subsets (T_H1 T_H2, T_H17, T_{FH}), in line with the activated
386 and aberrant cytokine phenotype observed (**Figure 6F-P**). Similarly, annotation based
387 on CD45RA AbSeq/HLA-DR AbSeq expression to identify CD45RA⁺HLA-DR⁻ naïve,
388 CD45RA⁻HLA-DR⁺ activated, and CD45RA⁻HLA-DR⁻ Tregs^{50,51} also found that P1 Tregs
389 were predominantly CD45RA⁻HLA-DR⁺ and CD45RA⁻HLA-DR⁻. (**Figure 7B**).
390 Nevertheless, P1 Treg subsets were transcriptomically similar to control Tregs (**Figure**
391 **7C-E, Figure S6B-D**), except for significantly increased *IL2*, *PDCD1*, and *CCR4*
392 transcript abundance in P1 naïve Tregs (**Figure 7C**), consistent with our flow cytometry
393 data (**Figure 6F-H**).

394 **scRNA-seq reveals a predominantly memory and effector phenotype in P1 CD4⁺** 395 **Tconvs**

396 Given the profound CD4 phenotype, we also sorted CD4⁺CD25⁻CD127⁺ Tconv cells
397 from P1 and two age-matched/sex-matched controls and performed scRNA-seq (P1
398 n=854 cells; control n=1225 cells) (**Figure S7A**). Like Tregs, P1 Tconv clustered
399 separately from controls and were frequently labelled as T_H subsets (**Figure 7F**) and
400 CD45RA⁻ memory (**Figure 7G**). When comparing the transcriptome of AbSeq-inferred
401 naïve (**Figure 7H, Figure S7E**) and memory (**Figure 7I, Figure S7F**) CD4⁺ Tconv cells

402 between P1 and controls, we found similar memory, but distinctly different naïve
403 populations. Unstimulated naïve P1 CD4⁺ Tconv cells had significantly higher transcript
404 abundance of genes related to IL-2 signalling, activation, and migration (*IL2RB*, *CXCR4*,
405 *PDCD1*, *CCL5*, *JUN*). Stimulated P1 CD4⁺ Tconv cells had significantly higher
406 expression of proinflammatory cytokine/chemokine genes (*IL2*, *IFNG*, *TNF*, *CCL4*),
407 confirming our CD4⁺ phenotyping data (**Figure 5K-P**).

408 **P1 CD4⁺ Tconvs are poised for T_H differentiation**

409 To study what pathways could be driving naïve CD4⁺ Tconv differences, we carried out
410 gene set enrichment analyses. Unstimulated naïve P1 CD4⁺ Tconv cells were more
411 enriched in pathways related to proliferation, IL-6 signalling, allograft rejection,
412 apoptosis, and hypoxia. Further, stimulated patient CD4⁺ Tconv cells showed significant
413 enrichment in proliferation (Myc targets V1/V2), metabolism (glycolysis,
414 gluconeogenesis, mTORC1 signaling), Treg survival (IL-2-STAT5), impaired tolerance
415 (allograft rejection), atopy (TSLP pathway), and T_H differentiation (IL-27-/IL-12-/IL-23-
416 mediated signalling events, T_H1, T_H2, T_H17 cell differentiation) pathways (**Figure 7J**). In
417 line with the primed/poised phenotype of P1 naïve CD4⁺ Tconv cells, we observed
418 significantly increased IL-2⁺ (**Figure 7K-L**), IFN- γ ⁺ (**Figure 7M-N**), and TNF- α ⁺ (**Figure**
419 **7O-P**) naïve P1 CD4⁺ T cells, with a similar trend observed in memory.

420

421 DISCUSSION

422 Germline pathogenic variants in *IKZF2* have only been discovered in humans in the
423 past two years. The initial descriptions were of germline heterozygous or homozygous
424 LOF *IKZF2* variants in a total of 13 patients with combined immunodeficiency and/or
425 immune dysregulation⁷⁻⁹ (summarized in **Figure S7A, Table S3**). Collectively, these
426 germline LOF *IKZF2* variants were predominantly heterozygous (10/13) and were
427 mostly associated with evidence of immune dysregulation (10/13) (**Table S4**), including
428 systemic lupus erythematosus (SLE), hemophagocytic lymphohistiocytosis (HLH),
429 idiopathic thrombocytopenic purpura (ITP), and Evan's syndrome. Our group recently
430 expanded this list through the discovery of 2 patients with germline DN *IKZF2* variants
431 who presented with ICHAD syndrome¹⁰. Notably the patient carrying the DN pathogenic
432 c.406+540_574+13477dup;p.Gly136_Ser191dup *IKZF2* variant (designated P1)
433 experienced the most severe clinical manifestations of immune dysregulation out of all
434 15 patients described to date with pathogenic germline *IKZF2* variants (**Figure S7B**). P1
435 presented with syndromic developmental features plus significant chronic AIHA and
436 atopic dermatitis, features consistent with classification as a PIRD. Given the profound
437 immune dysregulation associated with the DN pathogenic
438 c.406+540_574+13477dup;p.Gly136_Ser191dup *IKZF2* variant, we embarked on a
439 detailed immunological assessment of P1.

440 Immunophenotyping of this patient with DN *IKZF2* deficiency revealed striking
441 differences from previous homozygous and heterozygous LOF patients and mice. For
442 example, P1 NK cells were phenotypically immature and likely hyperactive due to
443 elevated IFN- γ production and reduced intracellular perforin and granzyme B expression
444 (**Figure 3**). In contrast, other reported patients had NK cell lymphopenia^{8,9} or normal NK
445 development⁷. Furthermore, while *IKZF2*^{-/-} mice have normal NK cell frequencies²¹, NK
446 cells from NKp46-mutant mice (Noé) show elevated Helios expression and effector
447 function, which modulates protective memory CD4⁺/CD8⁺ T cell development⁵². The
448 study of P1 has thus revealed a previously unappreciated role for Helios in human NK
449 cell development and function and calls for more in-depth studies in the future.

450 Helios has been extensively studied in mouse Tregs⁴², but its role in human Tregs has
451 remained relatively unclear. Previous CRISPR-mediated KO studies by our co-authors
452 found that Helios is dispensable for lineage stability and suppressive function in fully
453 differentiated Tregs²⁷, whereas germline homozygous or heterozygous LOF *IKZF2*
454 variants caused a proinflammatory Treg phenotype associated with increased IL-2 and
455 IFN- γ production, but intact suppressive function^{7,8}. Our functional studies with this DN
456 *IKZF2* variant confirm that it is not required for Treg development, but that it is essential
457 for inhibition of IL-2 expression and many other cytokines. Although functional
458 suppression of T cell proliferation appeared normal, aberrant production of many T_H
459 cytokines likely contributes to a functional defect in immune regulation *in vivo* (**Figure**
460 **6**), which is exacerbated by the greater propensity of P1 naïve CD4⁺ T cells to
461 differentiate into effector CD4⁺ T cell subsets (T_H1, T_H2, T_H9, T_{FH}).

462 Taken together, we have defined the immune phenotype of a novel form of Helios
463 deficiency caused by a DN variant, which leads to severe congenital AIHA and atopic
464 dermatitis¹⁰. This study identifies new players in the pathogenesis of these immune-
465 mediated disorders and has significantly expanded our understanding of human Helios,
466 including its regulation of naïve CD4 T cell differentiation into memory/effector subsets
467 and NK cell development and function.

468

469 **ACKNOWLEDGEMENTS**

470 This work was supported in part by grants from the Canadian Institutes of Health
471 Research (PJT 178054 to S.E.T.; FDN-154304 to M.K.L.), Genome British Columbia
472 (SIP007) (S.E.T.), and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada
473 Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of
474 Pediatric Immunology. M.K.L. receives a BCCHR salary award and holds a Tier 1
475 Canada Research Chair in Engineered Immune Tolerance. H.Y.L. is supported by a
476 CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral
477 Award (CGS-D), University of British Columbia Four Year Doctoral Fellowship (4YF),
478 Killam Doctoral Scholarship, Friedman Award for Scholars in Health, and a BC
479 Children's Hospital Research Institute Graduate Studentship. M.V.S. is supported by a
480 Vanier Canada Graduate Scholarship and 4YF. A.J.L. is supported by a CGS-D and
481 4YF. M.S. is supported by a CGS-D and 4YF. We would like to acknowledge the Flow
482 Cytometry and Imaging cores at BC Children's Hospital Research Institute for providing
483 the equipment for microscopy, flow cytometry, and cell sorting, the Biomedical
484 Research Centre Sequencing Core (BRC-Seq) for their assistance with single-cell RNA
485 sequencing and data processing, The Centre for Applied Genomics, The Hospital for
486 Sick Children, Toronto, Canada for their assistance with whole genome sequencing,
487 and the BC Children's Hospital BioBank for providing access to age-matched and sex-
488 matched control peripheral blood mononuclear cells.

489 **AUTHORSHIP CONTRIBUTIONS**

490 H.Y.L, A.L., and S.E.T. were responsible for study conception and design. H.Y.L.,
491 M.V.S., A.J.L., M.S., J.G., G.X.Y., S.L. performed experiments. A.M., C.V., A.L., S.M.
492 conducted genetic screening and variant prioritization. H.Y.L., M.S., M.P.F., M.S.K., A.M
493 performed bioinformatics analyses or provided computational resources. H.Y.L., M.V.S.,
494 A.S., R.R., L.A., J.H., C.L.Y., M.C., E.H., Au.S., F.K.K., K.J.H., C.M.B., C.V., A.L.,
495 S.E.T. collected and analyzed clinical data. H.Y.L., M.V.S., A.J.L., M.S., A.M., J.G.,
496 G.X.Y., M.K.L., S.E.T. analyzed and interpreted data. H.Y.L. and S.E.T. wrote the
497 manuscript with input from all authors. All authors read and approved the final version of
498 the manuscript.

499 **DISCLOSURE OF CONFLICTS OF INTEREST**

500 The authors declare no competing financial interests.

501

502

503 **REFERENCES**

504

- 505 1. Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing
506 universe of immune dysregulation. *Curr Opin Allergy Clin Immunol*. 2020;20(6):582-590.
- 507 2. Flinn AM, Gennery AR. Primary immune regulatory disorders: Undiagnosed
508 needles in the haystack? *Orphanet J Rare Dis*. 2022;17(1):99.
- 509 3. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies:
510 pathomechanisms, novel differential diagnoses, and treatment. *Blood*.
511 2014;124(15):2337-2344.
- 512 4. Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E,
513 Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and
514 perspectives. *Immun Ageing*. 2020;17(1):38.
- 515 5. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias.
516 *Haematologica*. 2014;99(10):1547-1554.
- 517 6. Tranekaer S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm
518 Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. *J Clin Med*.
519 2021;10(6).
- 520 7. Hetemaki I, Kaustio M, Kinnunen M, et al. Loss-of-function mutation in IKZF2
521 leads to immunodeficiency with dysregulated germinal center reactions and reduction of
522 MAIT cells. *Sci Immunol*. 2021;6(65):eabe3454.
- 523 8. Shahin T, Kuehn HS, Shoeb MR, et al. Germline biallelic mutation affecting the
524 transcription factor Helios causes pleiotropic defects of immunity. *Sci Immunol*.
525 2021;6(65):eabe3981.
- 526 9. Shahin T, Mayr D, Shoeb MR, et al. Identification of germline monoallelic
527 mutations in IKZF2 in patients with immune dysregulation. *Blood Adv*. 2022;6(7):2444-
528 2451.
- 529 10. Mohajeri A, Vaseghi-Shanjani M, Rosenfeld JA, et al. Dominant negative variants
530 in IKZF2 cause ICHAD syndrome, a new disorder characterised by
531 immunodysregulation, craniofacial anomalies, hearing impairment, athelia and
532 developmental delay. *J Med Genet*. 2023.
- 533 11. Kelley CM, Ikeda T, Koipally J, et al. Helios, a novel dimerization partner of
534 Ikaros expressed in the earliest hematopoietic progenitors. *Curr Biol*. 1998;8(9):508-
535 515.
- 536 12. Hahm K, Cobb BS, McCarty AS, et al. Helios, a T cell-restricted Ikaros family
537 member that quantitatively associates with Ikaros at centromeric heterochromatin.
538 *Genes Dev*. 1998;12(6):782-796.
- 539 13. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios
540 in human CD4(+)CD25(+) regulatory T cells. *Mol Immunol*. 2010;47(7-8):1595-1600.
- 541 14. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a
542 marker of T cell activation and proliferation. *PLoS One*. 2011;6(8):e24226.
- 543 15. Serre K, Benezech C, Desanti G, et al. Helios is associated with CD4 T cells
544 differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3
545 expression. *PLoS One*. 2011;6(6):e20731.
- 546 16. Leeansyah E, Svard J, Dias J, et al. Arming of MAIT Cell Cytolytic Antimicrobial
547 Activity Is Induced by IL-7 and Defective in HIV-1 Infection. *PLoS Pathog*.
548 2015;11(8):e1005072.

- 549 17. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros
550 transcription factor family member, differentiates thymic-derived from peripherally
551 induced Foxp3+ T regulatory cells. *J Immunol.* 2010;184(7):3433-3441.
- 552 18. Thornton AM, Lu J, Korty PE, et al. Helios(+) and Helios(-) Treg subpopulations
553 are phenotypically and functionally distinct and express dissimilar TCR repertoires. *Eur*
554 *J Immunol.* 2019;49(3):398-412.
- 555 19. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T
556 cells requires the transcription factor Helios. *Science.* 2015;350(6258):334-339.
- 557 20. Sebastian M, Lopez-Ocasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM.
558 Helios Controls a Limited Subset of Regulatory T Cell Functions. *J Immunol.*
559 2016;196(1):144-155.
- 560 21. Cai Q, Dierich A, Oulad-Abdelghani M, Chan S, Kastner P. Helios deficiency has
561 minimal impact on T cell development and function. *J Immunol.* 2009;183(4):2303-2311.
- 562 22. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T
563 cells being driven to tolerance in the periphery and thymus. *Eur J Immunol.*
564 2014;44(7):2048-2058.
- 565 23. Skadow M, Penna VR, Galant-Swofford J, Shevach EM, Thornton AM. Helios
566 Deficiency Predisposes the Differentiation of CD4(+)Foxp3(-) T Cells into Peripherally
567 Derived Regulatory T Cells. *J Immunol.* 2019;203(2):370-378.
- 568 24. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and
569 Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. *J*
570 *Immunol.* 2013;190(5):2001-2008.
- 571 25. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced
572 Foxp3+ regulatory T cells. *J Immunol.* 2012;188(3):976-980.
- 573 26. Ng MSF, Roth TL, Mendoza VF, Marson A, Burt TD. Helios enhances the
574 preferential differentiation of human fetal CD4(+) naive T cells into regulatory T cells. *Sci*
575 *Immunol.* 2019;4(41).
- 576 27. Lam AJ, Uday P, Gillies JK, Levings MK. Helios is a marker, not a driver, of
577 human Treg stability. *Eur J Immunol.* 2022;52(1):75-84.
- 578 28. Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ. Instability of
579 Helios-deficient Tregs is associated with conversion to a T-effector phenotype and
580 enhanced antitumor immunity. *Proc Natl Acad Sci U S A.* 2016;113(22):6248-6253.
- 581 29. Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the combined
582 immunodeficiency in complete human CARD11 deficiency. *J Allergy Clin Immunol.*
583 2021;148(6):1559-1574 e1513.
- 584 30. Sharma M, Fu MP, Lu HY, et al. Human complete NFAT1 deficiency causes a
585 triad of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022.
- 586 31. Chessum L, Matern MS, Kelly MC, et al. Helios is a key transcriptional regulator
587 of outer hair cell maturation. *Nature.* 2018;563(7733):696-700.
- 588 32. Baine I, Basu S, Ames R, Sellers RS, Macian F. Helios induces epigenetic
589 silencing of IL2 gene expression in regulatory T cells. *J Immunol.* 2013;190(3):1008-
590 1016.
- 591 33. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development,
592 Maturation, and Clinical Utilization. *Front Immunol.* 2018;9:1869.
- 593 34. Burk CM, Coffey KE, Mace EM, et al. Immunodeficiency, centromeric instability,
594 and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy

- 595 treated with stem cell transplantation. *J Allergy Clin Immunol Pract.* 2020;8(3):1103-
596 1106 e1103.
- 597 35. Ruiz-Garcia R, Vargas-Hernandez A, Chinn IK, et al. Mutations in PI3K110delta
598 cause impaired natural killer cell function partially rescued by rapamycin treatment. *J*
599 *Allergy Clin Immunol.* 2018;142(2):605-617 e607.
- 600 36. Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, et al. PD-1+CD8+ T cells
601 are clonally expanding effectors in human chronic inflammation. *J Clin Invest.*
602 2018;128(10):4669-4681.
- 603 37. Smirnova SJ, Sidorova JV, Tsvetaeva NV, et al. Expansion of CD8+ cells in
604 autoimmune hemolytic anemia. *Autoimmunity.* 2016;49(3):147-154.
- 605 38. Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword:
606 Harnessing PD-1 blockade in tumor and autoimmunity. *Sci Immunol.*
607 2021;6(65):eabf4034.
- 608 39. Heizmann B, Kastner P, Chan S. The Ikaros family in lymphocyte development.
609 *Curr Opin Immunol.* 2018;51:14-23.
- 610 40. Dovat S, Montecino-Rodriguez E, Schuman V, Teitell MA, Dorshkind K, Smale
611 ST. Transgenic expression of Helios in B lineage cells alters B cell properties and
612 promotes lymphomagenesis. *J Immunol.* 2005;175(6):3508-3515.
- 613 41. Zhu X, Zhu J. CD4 T Helper Cell Subsets and Related Human Immunological
614 Disorders. *Int J Mol Sci.* 2020;21(21).
- 615 42. Thornton AM, Shevach EM. Helios: still behind the clouds. *Immunology.*
616 2019;158(3):161-170.
- 617 43. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory
618 T Cells and Human Disease. *Annu Rev Immunol.* 2020;38:541-566.
- 619 44. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in
620 regulatory T cells. *PLoS Biol.* 2007;5(2):e38.
- 621 45. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3
622 gene expression. *Eur J Immunol.* 2008;38(6):1654-1663.
- 623 46. Wang ES, Verano AL, Nowak RP, et al. Acute pharmacological degradation of
624 Helios destabilizes regulatory T cells. *Nat Chem Biol.* 2021;17(6):711-717.
- 625 47. Yates K, Bi K, Haining WN, Cantor H, Kim HJ. Comparative transcriptome
626 analysis reveals distinct genetic modules associated with Helios expression in
627 intratumoral regulatory T cells. *Proc Natl Acad Sci U S A.* 2018;115(9):2162-2167.
- 628 48. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and
629 Projection for Dimension Reduction; 2018:arXiv:1802.03426.
- 630 49. Schmiedel BJ, Singh D, Madrigal A, et al. Impact of Genetic Polymorphisms on
631 Human Immune Cell Gene Expression. *Cell.* 2018;175(6):1701-1715 e1716.
- 632 50. Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human
633 CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-
634 versus-host disease. *Blood.* 2013;122(10):1802-1812.
- 635 51. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. *Nat Rev*
636 *Immunol.* 2016;16(2):90-101.
- 637 52. Narni-Mancinelli E, Jaeger BN, Bernat C, et al. Tuning of natural killer cell
638 reactivity by NKp46 and Helios calibrates T cell responses. *Science.*
639 2012;335(6066):344-348.
- 640

641

642 **TABLE LEGENDS**

643 **Table 1. Summary of major hematological and immunological laboratory**
644 **parameters.** Tabulation of patient hematological and immunological laboratory values
645 compared to age-specific reference ranges. †value measured while patient was on
646 intravenous immunoglobulin replacement. TREC, T cell receptor excision circle; DAT,
647 direct antiglobulin test; HGB, hemoglobin.

648 **FIGURE LEGENDS**

649 **Figure 1. Clinical phenotype of the patient.** A) Family pedigree of the patient. Filled
650 symbols indicate affected individuals. Arrow represents index patient. Known genotype
651 is marked. B-I) Hematological parameters measured in the patient over time. Shaded
652 regions=age-specific reference ranges. J) Sanger sequencing of DNA extracted from
653 whole blood of the patient. Primers were designed to flank the breakpoint. K) Schematic
654 representation of the impact of i) the c.406+540_574+13477dup *IKZF2* variant on the
655 genomic level. Red inset=exon 5 duplication. Blue inset=Sanger sequencing primer
656 location; and ii) the p.Gly136_Ser191dup Helios variant on the protein level. Red
657 inset=zinc finger 2 and 3 duplication. Var., variant; WT, wild-type; ZF, zinc finger; P1,
658 patient 1.

659 **Figure 2. A novel *IKZF2* variant leads to reduced Helios protein expression and**
660 **dominant interference of WT function.** A-B) HEK293 cells were transfected with
661 empty vector (EV), wild-type (WT) *IKZF2*, or p.Gly136_Ser191dup (variant) *IKZF2* alone
662 or in different combinations. Expression was determined by immunoblotting with both
663 FLAG and Helios. n=5. C-E) Expression of Helios was detected in patient-derived and
664 control lymphoblastoid cell lines (LCLs) and compared to negative (THP-1 monocytic
665 cells) and positive (Jurkat T leukemia cells) controls by C-D) immunoblot and E) flow
666 cytometry. F) HEK293 cells were transfected with EV, WT, variant, or ratios of
667 WT:variant and subjected to immunofluorescence for detection of Helios (red, Alexa
668 Fluor 647), the nucleus (blue, DAPI), and F-actin (green, Phalloidin Alexa Fluor 488)
669 using a Leica SP5 Confocal and LAS X Software with a 100x objective lens. Scale

670 bars=5 μ m. n=3. G-H) HEK293 cells were cotransfected with EV, *IKZF2* expression
671 plasmids at various ratios, pIL2-luc2, and Renilla luciferase. *IL2* promoter activity was
672 defined as relative light units from different conditions normalized to EV. H) Pearson
673 correlation between *IL2* promoter activity and % variant/WT *IKZF2* plasmid transfected.
674 Shaded region=95% confidence interval. n=3. *p<0.05, **p<0.01, ***p<0.001,
675 ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test.

676 **Figure 3. P1 has impaired NK cell development and function.** A) Representative
677 flow cytometry dot plots showing CD3⁺CD56⁻ T cells, CD3⁻CD56⁺ NK cells, and
678 CD3⁺CD56⁺ NKT cells for P1 and a control. B-D) Frequency of B) T cells, C) NK cells,
679 D) NKT cells from A) in P1 and adult (HC^A) and pediatric (HC^P) controls. E)
680 Representative Helios histograms for T, NK, and NKT cells in P1 and controls
681 compared to a fluorescence minus one (FMO) control. Mean fluorescence intensities
682 (MFI) are indicated. F-H) Quantification of Helios MFI in F) T cells, G) NK cells, H) NKT
683 cells from P1 and controls. I-N) Frequency of I) CD56^{dim}, J) CD56^{bright} NK, K) CD16⁺, L)
684 CD57⁺, M) CD27⁺, N) CD94⁺ NK cells in P1 compared to controls. O-P) Frequency of N)
685 CD8⁺ and P) CD25⁺ NK cells in patient and controls before and after 4h PMA and
686 ionomycin (P/I) stimulation. Q-R) Frequency of Q) IFN- γ ⁺ and R) TNF- α ⁺ NK cells in P1
687 and controls after P/I stimulation. S-T) MFI of S) granzyme B and T) perforin in
688 unstimulated P1 and control NK cells. U-V) Live NK cells from P1 or controls clustered
689 on CD16, CD27, CD57, CD94, Helios, perforin, granzyme B, IFN- γ , and TNF- α . Number
690 of NK cells clustered for each group is indicated on the panels to the right. V) tSNE plots
691 from U) coloured based on CD16, CD27, CD56, CD57, or CD94 expression. A-N, Q-T)
692 P1 n=5, HC^A n=8, HC^P n=11. O-P) P1 n=3, HC n=8. *p<0.05, **p<0.01, ***p<0.001,
693 ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test.

694 **Figure 4. P1 CD8⁺ T cells are more differentiated and have enhanced cytokine**
695 **production.** A) Representative dot plots showing CD3⁺CD4⁻CD8⁺ and CD3⁺CD4⁺CD8⁻
696 T cells. B) Frequency of CD8⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P) controls.
697 C) Representative contour plot of naïve (N), central memory (CM), effector memory
698 (EM), and TEMRA CD8⁺ T cells in the patient and a control. Quadrants corresponding
699 to each subset are shown to the right. D-G) Quantification of D) naive, E) CM, F) EM, G)

700 TEMRA CD8⁺ T cells from C). H) Representative Helios histograms for CD8⁺ T cells
701 from P1 and three controls compared to a fluorescence minus one (FMO) control. Mean
702 fluorescence intensities (MFI) are indicated. I) Quantification of Helios MFI in different
703 CD8⁺ T cell subsets. J) Representative contour plots for PD-1⁺ CD8⁺ T cells in P1 and a
704 control. K) Quantification of J). L-Q) PBMCs stimulated 4h with PMA+ionomycin. L), O)
705 Representative contour plots for L) TNF- α ⁺ and O) IFN- γ ⁺ CD8⁺ T cells in P1 and a
706 control. M-N) Quantification of TNF- α ⁺ M) naïve and N) total memory CD8⁺ T cells. P-Q)
707 Quantification of IFN- γ ⁺ P) naïve and Q) total memory CD8⁺ T cells. A-Q) P1 n=5, HC^A
708 n=8, HC^P n=11. J-K) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
709 Ordinary one-way ANOVA with Šidák's multiple comparisons test. R) Representative
710 histograms for dilution of Cell Proliferation Dye (CPD) eF450 in P1 or control CD8⁺ T
711 cells after 4 days of stimulation with anti-CD3/CD28 beads at 1:32 bead to cell ratio. S)
712 Quantification of percent divided CD8⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios.
713 Shown are technical duplicates.

714 **Figure 5. P1 CD4⁺ T cells are hyperactive and exhibit enhanced effector function.**

715 A) Quantification of frequency of CD4⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P)
716 controls. B) Representative contour plot of naïve (N), central memory (CM), effector
717 memory (EM), and TEMRA CD4⁺ T cells in the patient and a control. Quadrants
718 corresponding to each subset are shown to the right. C-F) Quantification of C) naïve, D)
719 CM, E) EM, F) TEMRA CD4⁺ T cells from B). G) Representative Helios histograms for
720 CD4⁺ T cells in P1 and three controls compared to a fluorescence minus one (FMO)
721 control. Mean fluorescence intensities (MFI) are indicated. H) Quantification of Helios
722 MFI in different CD4⁺ T cell subsets. I) Representative contour plots for PD-1⁺ CD4⁺ T
723 cells in P1 and a control. J) Quantification of I). K-V) PBMCs stimulated 4h with
724 PMA+ionomycin. K), M), O), Q), T) Representative contour plots for K) IL-2⁺ CD4⁺ M)
725 IFN- γ ⁺ CD4⁺, O) TNF- α ⁺ CD4⁺, Q) IFN- γ ⁺IL-4⁻ T_{H1} and IFN- γ ⁺IL-4⁺ T_{H2}, T) IL-21⁺IL-9⁻ T_{FH}
726 and IL-21⁻IL-9⁺ T_{H9} cells in P1 and a control. Quadrant identities are shown on the
727 bottom right. Frequencies corresponding to each quadrant are included to the top right
728 of each panel. L), N), P), R-S), U-V) Quantification of L) IL-2⁺ CD4⁺, N) IFN- γ ⁺ CD4⁺, P)
729 TNF- α ⁺ CD4⁺, R) T_{H1}, S) T_{H2}, U) T_{H9}, V) T_{FH} cells. A-H), K-V) P1 n=5, HC^A n=8, HC^P


730 n=11. I-J) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Ordinary one-
731 way ANOVA with Šidák's multiple comparisons test. W-Y) PBMCs stimulated with anti-
732 CD3/CD28 beads at various bead to cell ratios for 4 days. W) T_H cytokines measured by
733 LEGENDplex. X) Representative histograms for dilution of Cell Proliferation Dye (CPD)
734 eF450 in P1 or control CD4⁺ T cells stimulated at 1:32 bead to cell ratio. Y)
735 Quantification of percent divided CD4⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios.
736 Shown are technical duplicates.

737 **Figure 6. P1 Tregs have aberrant cytokine production and impaired suppressive**
738 **function.** A) Quantification of frequency of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺
739 Tregs in P1 and adult (HC^A) or pediatric (HC^P) controls. B) Representative Helios
740 histograms for Tregs in P1 and three controls compared to a fluorescence minus one
741 (FMO) control. Mean fluorescence intensities (MFI) are indicated. C) Quantification of
742 Helios MFI in Tregs. D) CpG methylation of the Treg-specific demethylated region
743 (TSDR) for P1 or control Tregs and Tconvs. Percent methylation at different TSDR CpG
744 sites is indicated. Representative of n=2. E) Quantification of FOXP3 MFI in Tregs. F)
745 Quantification of PD-1⁺ Tregs. G-O) PBMCs stimulated 4h with PMA+ionomycin. G), I),
746 N) Representative contour plots for G) IL-2⁺, I) IFN- γ ⁺, IL-4⁺, and N) TNF- α ⁺ Tregs. H),
747 J-M), O) Quantification of H) IL-2⁺, J) IL-4⁺, K) IFN- γ ⁺, L) IL-9⁺, M) IL-21⁺, O) TNF- α ⁺
748 Tregs. A-C), E), J-O) P1 n=5, HC^A n= 10, HC^P n=12. F-H) P1 n=3, HC^A n=8. *p<0.05,
749 **p<0.01, ***p<0.001, ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple
750 comparisons test. P) Isolated and expanded Tregs stimulated with anti-CD3/CD28
751 beads for 4 days. T_H cytokines measured by LEGENDplex. Shown are 3 technical
752 replicates. Q-R) Isolated and expanded Tregs co-cultured at different ratios with control
753 CD3⁺ T responder (Tresp) cells. n=2. Q-R) Suppression of Q) CD4⁺ and R) CD8⁺ T cell
754 proliferation. Significance determined by one-way ANOVA of areas under the curve. S)
755 T_H cytokines measured by LEGENDplex when co-culturing 1:16 bead:cell ratio
756 stimulated P1 CD3⁺ Tresp with control Tregs. Shown are technical triplicates.

757 **Figure 7. P1 naïve CD4⁺ T cells are more active and primed for effector function.**
758 A-E) Single-cell RNA sequencing (scRNA-seq) of sorted CD3⁺CD4⁺CD25⁺CD127^{lo}
759 Tregs from P1 and 2 age-matched and sex-matched controls. A) Unstimulated Tregs


760 clustered and annotated using the DICE project and B) CD45RA/HLA-DR AbSeq
761 labelling. Panels represent the controls and P1 Tregs clustered together (overall) or
762 control or P1 Tregs alone. Included are legends with colours and numbers
763 corresponding to each cell type labelled. Doughnut plots are included below each panel
764 to represent the frequency of each annotated cell type. C-E) Volcano plots comparing
765 stimulated patient and control C) CD45RA⁺HLA-DR⁻ naïve, D) CD45RA⁻HLA-DR⁺
766 activated, and E) CD45RA⁻HLA-DR⁻ Tregs. Red=significantly increased,
767 blue=significantly decreased, gray=non-significant. Vertical dashed line: fold
768 change=1.5, horizontal dashed line: FDR=0.05. Top 10 most significant genes are
769 labelled. F-H) scRNA-seq of sorted CD3⁺CD4⁺CD25⁻CD127^{hi} Tconv from P1 and 2 age-
770 matched and sex-matched controls. F-G) Unstimulated Tconv clustered and annotated
771 as in A-B). H-I) Volcano plots as in C-E) comparing stimulated patient and control H)
772 CD45RA⁺ naïve or I) CD45RA⁻ memory Tconvs. J) Gene set enrichment of differentially
773 expressed genes between stimulated naïve patient and control Tconvs using EnrichR.
774 Shown are the combined scores and adjusted p-values. H=MSigDB Hallmark,
775 B=BioPlanet 2019, N=NCI Nature 2016, K=KEGG 2021 Human. K-P) PBMCs
776 stimulated 4h with PMA+ionomycin. Quantification of stimulated K) IL-2⁺ naïve, L) IL-2⁺
777 total memory, M) IFN- γ ⁺ naïve, N) IFN- γ ⁺ total memory, O) TNF- α ⁺ naïve, and P) TNF- α ⁺
778 total memory CD4⁺ T cells. K-P) P1 n=5, HC^A n=8, HC^P n=11. ***p<0.001, ****p<0.0001.
779 Ordinary one-way ANOVA with Šidák's multiple comparisons test.

A.




medRxiv preprint doi: <https://doi.org/10.1101/2023.09.09.23295301>; this version posted September 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


B.




C.




D.




E.




F.




G.




H.



I.




J.




K.


i) **DNA**



ii) **Protein**



medRxiv preprint doi: <https://doi.org/10.1101/2023.09.09.23295301>; this version posted September 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).







Figure 3







Figure 5






Table 1

	Patient (0.5-5 yo)	Reference (0.5-5 yo)
Lymphocytes (x10 ⁹ /L)	*1.31	2.00 – 8.00
CD3 ⁺ T cells	1.14	0.90 – 4.50
CD4 ⁺ T cells	0.74	0.50 – 2.40
CD8 ⁺ T cells	*0.19	0.30 – 1.60
CD19 ⁺ B cells	0.52	0.20 – 2.10
TREC (copy number / 3μL)	*3.08	>75
Red blood cells (x10 ¹² /L)	*2.83	3.90 – 5.30
Reticulocytes (x10 ⁹ /L)	32	20-80
Nucleated red blood cells (x10 ⁹ /L)	*0.05	<0.01
Platelets (x10 ⁹ /L)	383	200-490
Mean platelet volume (fL)	9.9	8.60 – 11.6
Neutrophils (x10 ⁹ /L)	3.07	1.50 – 8.50
Monocytes (x10 ⁹ /L)	0.54	0.00 – 0.90
Hemoglobin (g/L)	*103	105 – 135
Hematocrit	*0.30	0.33 – 0.39
Mean corpuscular volume	*104	75 – 87
Mean corpuscular hemoglobin	*36	24 – 30
Prothrombin time (s)	9.9	9.6 – 11.9
International normalized ratio	0.9	0.9 – 1.1
Lactate dehydrogenase (U/L)	640	500 – 920
Antibody Response		
IgG (g/L)	6.7 [‡]	4.0 – 8.3
IgA (g/L)	0.63	0.18 – 1.00
IgM (g/L)	0.83	0.19 – 1.46
IgE (μg/L)	*242	<18
Tetanus antitoxin (IU/mL)	0.83	0.10 – 1.00
Diphtheria antitoxin (IU/mL)	0.70	0.50 – 1.10
DAT (polyspecific)	*Positive +3	Negative
Anti-IgG	*Positive +3	Negative
Anti-IgA	Negative	Negative
Anti-IgM	Negative	Negative
Anti-C3c	Negative	Negative
Anti-C3d	Negative	Negative
Hemoglobinopathy Workup		
HGB F	*0.044	0.000 – 0.011
HGB A	*0.831	0.848 – 0.920
HGB A2	0.029	0.022 – 0.034
BART's or HGB H Spike	Not detected	Not detected